Cáncer de mama metastásico HER2 positivo: ¿Cuál es la mejor primera línea de tratamiento?

Diego L. Kaen

doi:10.56969/oc.v20i1.100

Autores/as

Diego L. Kaen Centro Oncológico Riojano Integral (CORI), La Rioja https://orcid.org/0000-0002-5229-0164

DOI:

https://doi.org/10.56969/oc.v20i1.100

Palabras clave:

HER2, cáncer de mama metastásico, pertuzumab, tratamiento dirigido, metastatic breast cancer, targeted therapy

Resumen

El cáncer de mama metastásico (CMM) no tratado, positivo para el receptor-2 de factor de crecimiento epidérmico humano (HER2) es una enfermedad agresiva, asociada con mal pronóstico y supervivencia global (SG) corta. El tratamiento dirigido a HER2, cuando se combina con quimioterapia, prolonga tanto el tiempo hasta la progresión de la enfermedad como la supervivencia global, y se ha convertido en el tratamiento de referencia para los casos de cáncer de mama HER2-positivos en contextos temprano y avanzado. Pese a la notable repercusión terapéutica que ha tenido el tratamiento dirigido a HER2, la supervivencia hasta los datos finales de SG del estudio CLEOPATRA, no superaba los38 meses de mediana. Este artículo realiza una revisión de los datos publicados en New England Journal of Medicine (NEJM) en febrero del 2015, haciendo especial atención en la supervivencia global y seguridad de los pacientes tratados con pertuzumab, trastuzumab y docetaxel con un seguimiento de 50 meses.

Citas

Siegel R, Naishadham D, Jemal A. Cancer statistcs, 2013. CA Cancer J Clin 2013; 63:11-30. DOI: https://doi.org/10.3322/caac.21166

Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010; 21:2169-74. DOI: https://doi.org/10.1093/annonc/mdq220

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14:320-68. DOI: https://doi.org/10.1634/theoncologist.2008-0230

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987; 235:177-82. DOI: https://doi.org/10.1126/science.3798106

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.

Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-74. DOI: https://doi.org/10.1200/JCO.2005.04.173

NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 1.2015.

US Food and Drug Administration. Lapatinib approval letter, 2007. En: http://www.accessdata.fda.gov/drugsatfda_docs/ appletter/2007/022059s000ltr.pdf.; consultado el 20/3/2015.

von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47:2273-81. DOI: https://doi.org/10.1016/j.ejca.2011.06.021

Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer 2014; 111: 1888-98. DOI: https://doi.org/10.1038/bjc.2014.388

Zelnak AB, Wisinski KB. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches? Cancer 2015; 121:17-24. DOI: https://doi.org/10.1002/cncr.28815

Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372:724-34. DOI: https://doi.org/10.1056/NEJMoa1413513

Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastu- zumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19. DOI: https://doi.org/10.1056/NEJMoa1113216

Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival result from a randomised, double blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-71. DOI: https://doi.org/10.1016/S1470-2045(13)70130-X

Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92. DOI: https://doi.org/10.1056/NEJM200103153441101

Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–over-expressing metastatic breast cancer. J Clin Oncol 2013; 31:1947-53. DOI: https://doi.org/10.1200/JCO.2011.40.5241

Baselga J, Cortés J, Im SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2–positive, first-line metastatic breast cancer. J Clin Oncol 2014; 32:3753-61. DOI: https://doi.org/10.1200/JCO.2013.54.5384

Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27:5529-37. DOI: https://doi.org/10.1200/JCO.2008.20.6847

Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012; 21:27-33. DOI: https://doi.org/10.1016/j.breast.2011.07.006

Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010; 15:122-9. DOI: https://doi.org/10.1634/theoncologist.2009-0240